Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991454 | 0.74 | — | — | |
| SCHEMBL1629938 | 0.72 | — | — | |
| SCHEMBL7418410 | 0.72 | HSP90AA1 (0.37) | SMN1; SMN2 | |
| SCHEMBL9302384 | 0.72 | SLC2A1 (0.40) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL3194915 | 0.71 | — | — | |
| SCHEMBL5301101 | 0.71 | PDE10A (0.43) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL7713660 | 0.69 | NOS3 (0.46) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL1850348 | 0.69 | ADRA2A (0.48) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL7047083 | 0.69 | MAOA (0.48) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL4913250 | 0.69 | NR4A1 (0.52) | MAOAMAOBRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | claimed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | claimed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| CN-1764380-A | N-phenyl- (4-pyridyl)- azinyl!amine derivatives as plant protection agents. | SYNGENTA PARTICIPATIONS AG (CH) | 2006-04-26 | — | — | CN | claimed |
| CN-1720244-A | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2006-01-11 | — | — | CN | claimed |
| EP-1572686-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2005-09-14 | — | — | EP | claimed |
| CN-1522256-A | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | 詹森药业有限公司 | 2004-08-18 | — | — | CN | claimed |
| WO-2004052884-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| CN-1334798-A | Phenylglycine derivatives | HOFFMANN LA ROCHE (CH) | 2002-02-06 | — | — | CN | claimed |
| EP-0509354-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-08-23 | — | — | EP | claimed |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | BALKAN BORK (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130122008-A1 | Anti-IL 1- ß Antibody Combination Therapy | NOVARTIS AG | 2013-05-16 | — | — | US | disclosed |
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-4996318-A | Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke | THE UPJOHN COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0354920-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1990-02-21 | — | — | EP | disclosed |
| WO-1988007527-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | ADRA2A 2080/4885ADRA2B 2070/4885ADRA2C 2110/4885 |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | DPP4, DPP7, DPP3 | ADRA2A 2511/4885ADRA2B 2642/4885ADRA2C 2176/4885 |
| US-20130122008-A1 | Anti-IL 1- ß Antibody Combination Therapy | G6PC1, FBP1, GCKR | ADRA2A 1050/4885ADRA2B 1194/4885ADRA2C 795/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | ADRA2A 1425/4885ADRA2B 1450/4885ADRA2C 1337/4885 |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | ADRA2A 792/4885ADRA2B 1993/4885ADRA2C 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.